Press release summary
Agilent Technologies said Nov. 10 that it launched SureSelect Cancer Research Pan Heme, a research-use-only next-generation sequencing solution developed with Roswell Park Comprehensive Cancer Center for genomic profiling of hematologic malignancies. The hybrid-capture panel examines 359 DNA genes and 124 RNA genes and is designed to assess single-nucleotide variants, insertions and deletions, copy-number changes, immunoglobulin translocations and gene fusions.
The workflow combines Agilent target-enrichment chemistry with automated sample preparation and bioinformatics. Laboratories can pair the panel with the Magnis NGS Prep System for cartridge-based, walkaway library preparation and enrichment, while QIAGEN Clinical Insight supports variant analysis and reporting. Agilent said manual and semiautomated configurations are also available. Roswell Park’s implementation supports sample-to-report turnaround of about 48 hours, according to the company.
Why it matters to laboratory readers
Hematologic tumor profiling often requires laboratories to coordinate DNA and RNA assays, complex enrichment steps and multiple analysis systems. A consolidated workflow may reduce hands-on work and simplify method transfer, although laboratories should evaluate panel coverage, validation needs, throughput, reporting software and total operating costs. The product is for research use only and is not cleared for diagnostic procedures.
Original release: Agilent Technologies’ Nov. 10 announcement.
Leave a Reply